

patients with chronic HCV infection during a long observation period.

Patients and methods

Study design

Between January 1992 and December 2003, 832 patients were identified who were positive for both anti-HCV, by a second or third-generation enzyme-linked immunosorbent assay (ELISA), and for HCV RNA by polymerase chain reaction (PCR). These patients underwent liver biopsy guided by ultrasonography (US) at the National Nagasaki Medical Center. Of the 832 patients, 125 (15.0%) were excluded according to the following criteria: (1) positive for hepatitis B surface antigen (HBsAg) ($n = 12$); (2) heavy habitual drinking defined as an average daily consumption of >100 g ethanol ($n = 26$); (3) presence of autoimmune hepatitis (AIH), primary biliary cirrhosis, or idiopathic portal hypertension ($n = 8$); (4) positive anti-nuclear antibody (defined as a titer of $>320\times$) without a diagnosis of AIH ($n = 8$); or (5) a short follow-up period (<180 days) ($n = 71$). The remaining 707 patients were analyzed retrospectively for the incidence of HCC. Their medical histories had been recorded, with the results of routine tests for blood cell counts, liver biochemical parameters, and markers for HCV infection at the time of US-guided liver biopsy at regular intervals. Complete blood cell counts and biochemical tests were performed, using automated procedures, at the clinical pathology laboratories of the National Nagasaki Medical Center. Informed consent was obtained from each patient included in the study, and the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a-priori approval by the institution's human research committee.

Staging of hepatic fibrosis

Liver biopsy was taken by fine-needle aspiration (18G or 16G sonopsy) guided by US. Liver tissue specimens were fixed in 10% formalin, embedded in paraffin, and stained with hematoxylin and eosin. They were evaluated for the stage of hepatic fibrosis by a pathologist according to the criteria of Desmet et al. [17].

HCV RNA, HCV core antigen, and HCV genotypes

HCV RNA was determined by reverse transcriptase (RT)-PCR using a commercial kit (Amplicor HCV; Roche Diagnostic Systems, Basel, Switzerland). HCV core antigen was determined using the lumispot EIKEN HCV

antigen assay (Eiken Chemicals, Tokyo, Japan). HCV core antigen levels were classified as low or high with the cutoff at 1,000 fmol/L [18, 19]. Genotypes of HCV were determined by RT-PCR with genotype-specific primers (HCV RNA core genotype; Roche Diagnostics, Tokyo, Japan) [20, 21].

Interferon therapy

During the observation period, 373 of the 707 (52.8%) patients received interferon (IFN) monotherapy, pegylated (PEG)-IFN monotherapy, combination therapy with IFN and ribavirin, or PEG-IFN and ribavirin. Sustained virological response (SVR) was defined as the absence of detectable HCV RNA by the end of treatment that persisted for longer than 6 months thereafter, while failure in meeting these criteria was judged as non-SVR. There was no relapse of viremia after 6 months among SVR patients.

Diagnosis of hepatocellular carcinoma

Patients were followed up with hematological and biochemical tests at intervals of 1–12 months. Liver imaging was performed by US at 6- to 12-month intervals in most patients at fibrosis stages F0–F2, while computed tomography (CT), magnetic resonance imaging (MRI), or US was performed at 3- to 6-month intervals in patients at fibrosis stages F3 and F4. HCC was diagnosed by typical vascular patterns on CT, MRI, or angiography, or by fine-needle biopsy of space-occupying lesions detected in the liver.

Statistical analysis

Continuous variables [platelet counts, albumin, total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alpha-fetoprotein (AFP), HCV core antigen] were dichotomized with respect to the median value or clinically meaningful values in a multivariate analysis. To estimate the cumulative risk of developing HCC, the Kaplan–Meier method and the log-rank test were used. Cox proportional hazards regression analysis was performed to evaluate risk factors for HCC. Analysis was performed by Bonferroni's correction and data analysis was performed with SPSS ver. 11.0 (SPSS, Chicago, IL, USA).

Results

Characteristics at enrollment

Table 1 lists the characteristics of the 707 patients at enrollment. The median age was 57.0 years; 120 (17.0%)

Table 1 Demographic, clinical, and virological characteristics of 707 patients persistently infected with hepatitis C virus (HCV)

Age (years)	57.0 (19–79)
Male	351 (49.6%)
Observation period (years)	8.2 ± 4.4 ^a
Interferon therapy	373 (52.8%)
Habitual alcohol intake	135 (19.1%)
Fibrosis stage	
F0/F1	273 (38.6%)
F2	193 (27.3%)
F3	121 (17.1%)
F4	120 (17.0%)
Platelet count (×10 ³ /mm ³)	156 (30–391)
Albumin (g/dL)	4.2 (2.7–5.3)
Total bilirubin (mg/dL)	0.7 (0.1–2.5)
Aspartate aminotransferase (AST; IU/L)	53 (11–422)
Alanine aminotransferase (ALT; IU/L)	82 (1–1,057)
Alpha-fetoprotein (AFP; ng/mL)	6 (1–510)
HCV core antigen	
≥1,000 fmol/L	539 (76.2%)
HCV genotype	
1b	510 (72.1%)
2a/2b	195 (27.6%)
Unknown	2 (0.3%)

Values are medians with ranges in parentheses, or means with SD in parentheses

^a Mean ± SD

patients were diagnosed histologically with liver cirrhosis (fibrosis stage: F4) and the remaining 587 had chronic hepatitis (fibrosis stage F0, F1, F2, or F3). The median value of AFP was 6 ng/mL. The average follow-up period was 8.2 years. The patients were classified into three categories by the level of AFP; 350 patients (49.5%) had AFP levels of <6 ng/mL, 254 (35.9%) had levels between 6 and 20 ng/mL, and the remaining 103 (14.6%) had levels of ≥20 ng/mL.

IFN therapy and IFN response

Of the 120 patients with cirrhosis (fibrosis stage F4), 46 (38.3%) received IFN while the remaining 74 (61.7%) did not. The proportions of IFN-treated patients showing an SVR were 40.8% (56/137) in patients with F1; 37.6% (44/117) in those with F2; 32.8% (24/73) in those with F3; and 32.6% (15/46) in those with F4.

Risk factors for HCC

Cox regression analysis was performed on several variables, including age, sex, alcohol consumption, IFN therapy during the observation period, and biochemical as well

as virological parameters. The following factors were identified as showing an increased risk for HCC by the univariate analysis: age; IFN therapy; fibrosis stage; platelet count; albumin; AST, ALT, and AFP levels; and HCV genotype (Table 2). Multivariate analysis was performed on these factors (Table 3), and the following were identified as independent risk factors: fibrosis stage (F4), AFP (6–20 and ≥20 ng/mL), age (≥57 years), and IFN therapy (SVR).

Development of HCC

During the follow-up period, HCC developed in 110 (15.6%) patients. Of the 110 patients with HCC, 58 (52.7%) were diagnosed with the disease by histological examination of biopsy-obtained or resected liver specimens. Of these 58 patients, 24 (41.3%) had hypovascular HCC.

Among the patients with HCC, only eight (7.2%) had AFP <6 ng/mL at the time of diagnosis of HCC. Figure 1 shows Kaplan–Meier estimates of the cumulative risk of HCC with respect to fibrosis stage at entry. The 10-year cumulative incidence rates of HCC for stages F0/F1, F2, F3, and F4 were 2.5, 12.8, 19.3, and 55.9%, respectively.

There were significant differences in cumulative incidence rates among the three groups of patients with different AFP levels. The 10-year cumulative risk of HCC was 6.0% in the 350 patients with AFP <6 ng/mL at the study entry, 24.6% in the 254 patients with AFP 6–20 ng/mL, and 47.3% in the 103 patients with AFP ≥20 ng/mL ($P < 0.001$) (Fig. 2). Of the 350 patients with AFP <6 ng/mL, 21 eventually developed HCC during the observation period. Fourteen of these 21 patients were ≥57 years old and 10 had fibrosis stage F3 or F4. In remarkable contrast, HCC ultimately developed in 84.5% of the patients with AFP ≥20 ng/mL.

The 10-year cumulative incidence rates of HCC were 3.1% in patients with SVR to IFN, 14.6% in patients with non-SVR, and 29.5% in the patients without IFN therapy (Fig. 3). Of the 139 patients with SVR, three (2.2%) eventually developed HCC during the observation period. These three patients had advanced fibrosis stages at the study entry (1 with F3 and 2 with F4). Figure 4 shows the cumulative incidence of HCC in the patients with different AFP levels, stratified by the fibrosis stage. In the patients with fibrosis stage F4, there were significant differences in HCC incidence between those with AFP levels of <6 and those with levels of ≥20 ng/mL.

Figure 5 shows the proportions of patients with different AFP levels stratified by the fibrosis stage. The proportion of patients with AFP <6 ng/mL decreased with the advance of fibrosis stage, and conversely, the proportion of patients with AFP ≥20 ng/mL increased with the advance of fibrosis stage. There was a strong correlation between AFP levels and the fibrosis stage.

Table 2 Factors increasing the risk for hepatocellular carcinoma (HCC), determined by univariate analysis

Features	Hazard ratio	P value
Age		
<57 years	1	
≥57 years	3.889	<0.001
Sex		
Female	1	
Male	1.146	0.475
Alcohol intake		
None	1	
Habitual	1.012	0.962
Interferon therapy		
None	1	
Non-SVR	0.523	0.002
SVR	0.063	<0.001
Fibrosis stage		
F0/F1	1	
F2	1.863	0.096
F3	3.985	<0.001
F4	13.045	<0.001
Platelet count		
≥150 × 10 ³ /mm ³	1	
<150 × 10 ³ /mm ³	4.644	<0.001
Albumin		
≥4.2 g/dL	1	
<4.2 g/dL	2.952	<0.001
Total bilirubin		
<0.7 mg/dL	1	
≥0.7 mg/dL	1.438	0.065
AST		
<53 IU/L	1	
≥53 IU/L	2.501	<0.001
ALT		
<82 IU/L	1	
≥82 IU/L	1.514	0.035
AFP		
<6 ng/mL	1	
6–20 ng/mL	4.628	<0.001
≥20 ng/mL	10.335	<0.001
HCV core antigen		
<1,000 fmol/L	1	
≥1,000 fmol/L	1.112	0.645
HCV genotype		
2a/2b	1	
1b	1.730	0.027

SVR sustained virological response

Table 3 Factors increasing the risk for HCC, determined by multivariate analysis

Features	Hazard ratio (95% CI)	P value
Fibrosis stage		
F0/F1	1	
F2	1.030 (0.471–2.253)	0.942
F3	1.682 (0.632–3.713)	0.198
F4	3.957 (1.861–8.411)	<0.001
AFP		
<6 ng/mL	1	
6–20 ng/mL	1.942 (1.066–3.538)	0.030
≥20 ng/mL	3.884 (2.014–7.433)	<0.001
Age		
<57 years	1	
≥57 years	2.026 (1.261–3.255)	0.004
Interferon therapy		
None	1	
Non-SVR	0.704 (0.453–1.094)	0.119
SVR	0.099 (0.029–0.334)	<0.001

CI confidence interval

Discussion

In the present study, four variables were identified as risk factors for HCC in patients with chronic HCV infection: fibrosis stage, AFP level, age, and IFN therapy. Previous reviews have analyzed risk factors for the development of HCC [3, 22–25]. Yoshida et al. [6] have reported that the annual incidence increases with the stage of liver fibrosis, from 0.5% in patients with stage F0 or F1 to 7.9% in patients with stage F4 (cirrhosis). In our study, the cumulative incidence of HCC increased along with the advance of fibrosis stage. AFP is used as a serological marker of HCC, and is employed in combination with US for screening HCC [3]. Several reports have shown an elevated AFP level as a risk factor for the development of HCC among patients infected with HCV [16, 25–32]. Most of the studied patients had cirrhosis that was not definitely diagnosed by clinical symptoms and ultrasonographic findings. There have been few studies on patients with chronic hepatitis C, in addition to those with cirrhosis [27]. Thus, it has been unclear whether elevated AFP levels are a risk factor for the development of HCC in patients infected with HCV. Against this background, we were prompted to analyze the utility of AFP as a risk factor for the development of HCC in patients who had been histologically diagnosed by US-guided liver biopsy. In the present study,

Fig. 1 Cumulative incidence of hepatocellular carcinoma (HCC) according to the fibrosis stage




Fig. 2 Cumulative incidence of HCC according to alpha-fetoprotein (AFP) levels





Fig. 3 Cumulative incidence of HCC according to interferon (IFN) therapy. SVR Sustained virological response







Fig. 4 Cumulative incidence of HCC according to AFP levels, stratified by the fibrosis stage

Fig. 5 Proportions of patients with three different AFP levels (<6 ng/mL, 6–20 ng/mL, and ≥20 ng/mL) at different fibrosis stages



among patients infected with HCV, including not only those with cirrhosis but also those with chronic hepatitis, we found AFP levels to be a dependable risk factor for HCC, in addition to the fibrosis stage. Of particular note, not only the patients with high AFP levels (≥ 20 ng/mL) but also those with even slightly elevated AFP levels (between 6 and 20 ng/mL) had increased risks for the development of HCC. In the patients in this study, the median AFP level was 6 ng/mL. It deviated slightly from serum levels of AFP in healthy adults that have been reported to range from 0.1 to 5.8 ng/mL [33]. Hence, we performed analyses by setting various AFP cutoff levels for

evaluating their performance as risk factors. However, there were no significant differences in the analysis with the use of AFP cutoff levels exceeding 7 ng/mL. On the basis of these observations, an AFP cutoff level of 6 ng/mL was adopted in this study. In previous reports, AFP levels were associated with advanced fibrosis stage in patients infected with HCV in the absence of HCC [34–38]. In the present study, AFP levels were elevated in parallel with advanced fibrosis stages and correlated well with the fibrosis stage. As the patients with even slightly elevated AFP levels, between 6 and 20 ng/mL, had moderately advanced liver fibrosis stages, these AFP levels could

indicate an elevated risk for HCC in patients with chronic HCV infection.

Hu et al. [36] found that an AFP level of 15.0 mg/mL could detect severe fibrosis with a sensitivity of 22.8% and specificity of 94.5%. Moreover, they reported, during observation for 6 months of patients with chronic hepatitis C, that AFP levels stayed within the normal range (<10 ng/mL) in 60%, were persistently elevated in 24%, and fluctuated in the remaining 15%. By multivariate analysis, they identified AST, INR, and fibrosis as risk factors for AFP levels of >10 ng/mL. In view of the correlation between AFP levels and fibrosis stages, the AFP level at the time of liver biopsy was taken into account in the analysis in the present study; ALT levels are reported to be persistently elevated in the majority (60%) of patients with chronic hepatitis C.

Liver biopsy is the gold standard for assessing hepatic fibrosis [8, 9]. However, the needle liver biopsy has a sampling error and is too invasive as a routine procedure [10, 11]. Therefore, AFP levels may be used as a noninvasive and predictive marker in place of the fibrosis stage. The platelet count is known to reflect the severity of chronic hepatitis C [12, 13], and is used to estimate the degree of fibrosis without resort to liver biopsy [12–14]. Previous reports have shown low platelet counts to represent a risk factor for HCC in cirrhotic patients [13, 15, 16]. Matsumura et al. [13] reported that age and serum platelet count were significant risk factors for the development of HCC, and as such, they were a major clinico-laboratory means of evaluating the fibrosis stage. In the present study, however, the platelet count was not an independent risk factor for HCC development. When Cox regression analysis was performed on variables other than the fibrosis stage, platelet count and serum albumin levels were identified as independent risk factors for the development of HCC (data not shown).

IFN has been used to treat patients with HCV infection. Failure to achieve an SVR to IFN-based therapies, and preexisting advanced hepatic fibrosis and/or cirrhosis, are major predictors of HCC [6, 23, 25, 39, 40]. In the present study, SVR emerged as an independent risk factor for the development of HCC, while non-SVR was not. However, the cumulative incidence rate of HCC in patients with non-SVR was lower than that in those without IFN therapy. These results suggest that the use of IFN in patients with HCV-related liver disease may be beneficial in preventing the development of HCC. Several Japanese cohort studies have demonstrated that IFN therapy reduces the incidence of HCC, not only in sustained virological responders but also in transient responders who have failed to eliminate HCV [6, 41–45]. In cirrhotic patients, Nishiguchi et al. [39] reported that the relative risk of patients with IFN- α treatment developing HCC was 0.067 in comparison with the control

group. In contrast, Valla et al. [46] could not prove any significant benefit for the prevention of HCC between patients with and without IFN treatment. Camma et al. [47] suggested a slight preventive effect of IFN on HCC development in patients with HCV-related cirrhosis. Shiffman et al. [48] have reported that continuous IFN therapy led to a decline in hepatic fibrosis despite the persistence of viremia. In addition, there are case reports that IFN therapy reduced AFP levels in virological nonresponders [49]. Murashima et al. [50] showed that IFN therapy, but not Strong Neo-Minophagen C (SNMC) (Glycyrrhizin, Tokyo, Japan), universally reduced basic AFP levels. In an *in vitro* study of the effects of IFN on an HCC cell line, IFN exhibited anti-tumor effects [51]. Taken together, these findings suggest that AFP levels may be useful for predicting the development of HCC during IFN-based treatments, including long-term low-dose IFN therapy.

There have been several reports on the relationship between chronological trends in platelet counts, AST or AFP levels, and the development of HCC [11, 26, 27, 52–54]. Taroa et al. [52, 53] showed that in patients with HCV-related cirrhosis, those with persistently high serum ALT levels had a high risk of developing HCC and multicentric carcinogenesis, whereas those with persistently low ALT levels faced a very low risk. Likewise, the dynamics of AFP levels in patients with chronic HCV infection may be useful to estimate the risk of developing HCC. Recently, Bruce et al. [32] found serial measurements of AFP helpful in identifying persons with advanced fibrosis. They used an AFP level of 8 ng/mL, the test manufacturer's upper limit of normal, as the evaluation of the risk of development of HCC. It is not certain whether or not AFP would be a risk factor of HCC development in patients with chronic liver disease of etiologies other than persistent HCV infection. Velazquez et al. [55] reported that an AFP level of >5 ng/mL at study entry was associated with the development of HCC in their univariate analysis but not in their multivariate analysis. They speculated that this could have been because the main causative factor of liver cirrhosis in their series was alcohol. Taken together, the findings of various studies suggest that the baseline AFP level may be more reliable as a predictive factor for the development of HCC in patients with HCV-related liver disease than in those with liver disease of other etiologies.

In conclusion, AFP is a noninvasive predictive marker for the development of HCC in patients infected with HCV. The present study indicates that not only high AFP levels (≥ 20 ng/mL) but also slightly elevated AFP levels, between 6 and 20 ng/mL, could indicate substantial risks for the development of HCC, complementing the fibrosis stage. In contrast, AFP levels of <6 ng/mL indicate a low risk of HCC development, irrespective of the liver fibrosis stage. IFN therapy significantly reduces the risk of the

development of HCC, especially in patients with an SVR to the therapy.

Acknowledgments This work was sponsored in part by grants from the Ministry of Health, Labour and Welfare of Japan.

References

- Afdhal NH. The natural history of hepatitis C. *Semin Liver Dis.* 2004;24(Suppl 2):3–8.
- Cohen J. Virology. Culture systems for hepatitis C virus in sight at last. *Science.* 2005;308:1539–41.
- Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. *Semin Liver Dis.* 2005;25:143–54.
- Alter MJ. Epidemiology of hepatitis C virus infection. *World J Gastroenterol.* 2007;13:2436–41.
- El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology.* 2007;132:2557–76.
- Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and non-cirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. *Ann Intern Med.* 1999;131:174–81.
- Liang TJ, Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. *Gastroenterology.* 2004;127:S62–71.
- Saadah S, Cammell G, Carey WD, Younossi Z, Barnes D, Easley K. The role of liver biopsy in chronic hepatitis C. *Hepatology.* 2001;33:196–200.
- Gebo KA, Herlong HF, Torbenson MS, Jenckes MW, Chander G, Ghanem KG, et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. *Hepatology.* 2002;36:S161–72.
- Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. *Am J Gastroenterol.* 2002;97:2614–8.
- Yu ML, Lin SM, Lee CM, Dai CY, Chang WY, Chen SC, et al. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. *Hepatology.* 2006;44:1086–97.
- Ono E, Shiratori Y, Okudaira T, Imamura M, Teratani T, Kanai F, et al. Platelet count reflects stage of chronic hepatitis C. *Hepatol Res.* 1999;15:192–200.
- Matsumura H, Moriyama M, Goto I, Tanaka N, Okubo H, Arakawa Y. Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C—a study of 527 patients at one establishment. *J Viral Hepat.* 2000;7:268–75.
- Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. *Am J Gastroenterol.* 2001;96:3142–6.
- Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. *Gut.* 2000;47:131–6.
- Rodríguez-Díaz JL, Rosas-Camargo V, Vega-Vega O, Morales-Espinosa D, Méndez-Reguera A, Martínez-Tlahuel JL, et al. Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term follow-up study. *Clin Oncol (R Coll Radiol).* 2007;19:197–203.
- Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. *Hepatology.* 1994;19:1513–20.
- Aoyagi K, Ohue C, Iida K, Kimura T, Tanaka E, Kiyosawa K, et al. Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. *J Clin Microbiol.* 1999;37:1802–8.
- Tanaka E, Ohue C, Aoyagi K, Yamaguchi K, Yagi S, Kiyosawa K, et al. Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA. *Hepatology.* 2000;32:388–93.
- Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. *J Gen Virol.* 1993;74(Pt 11):2391–9.
- Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. *J Clin Microbiol.* 1997;35:201–7.
- Aizawa Y, Shibamoto Y, Takagi I, Zeniya M, Toda G. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis. *Cancer.* 2000;89:53–9.
- Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. *Gastroenterology.* 2004;127:S35–50.
- Kiyosawa K, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Gad A, et al. Hepatocellular carcinoma: recent trends in Japan. *Gastroenterology.* 2004;127:S17–26.
- Bruix J, Sherman M. Management of hepatocellular carcinoma. *Hepatology.* 2005;42:1208–36.
- Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. *N Engl J Med.* 1991;325:675–80.
- Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. *N Engl J Med.* 1993;328:1797–801.
- Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. *Hepatology.* 1994;19:61–6.
- Ganne-Carrie N, Chastang C, Chapel F, Munz C, Pateron D, Sibony M, et al. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis. *Hepatology.* 1996;23:1112–8.
- Sangiovanni A, Colombo E, Radaelli F, Bortoli A, Bovo G, Casiraghi MA, et al. Hepatocyte proliferation and risk of hepatocellular carcinoma in cirrhotic patients. *Am J Gastroenterol.* 2001;96:1575–80.
- Ikeda K, Arase Y, Saitoh S, Kobayashi M, Someya T, Hosaka T, et al. Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts. *J Hepatol.* 2006;44:1089–97.
- Bruce MG, Bruden D, McMahon BJ, Christensen C, Homan C, Sullivan D, et al. Clinical significance of elevated alpha-fetoprotein in Alaskan Native patients with chronic hepatitis C. *J Viral Hepat.* 2008;15:179–87.
- Taketa K. Alpha-fetoprotein: reevaluation in hepatology. *Hepatology.* 1990;12:1420–32.
- Chu CW, Hwang SJ, Luo JC, Lai CR, Tsay SH, Li CP, et al. Clinical, virologic, and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C. *J Clin Gastroenterol.* 2001;32:240–4.

35. Lu LG, Zeng MD, Wan MB, Li CZ, Mao YM, Li JQ, et al. Grading and staging of hepatic fibrosis, and its relationship with noninvasive diagnostic parameters. *World J Gastroenterol*. 2003;9:2574–8.
36. Hu KQ, Kyulo NL, Lim N, Elhazin B, Hillebrand DJ, Bock T. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. *Am J Gastroenterol*. 2004;99:860–5.
37. Wilfredo Canchis P, Gonzalez SA, Isabel Fiel M, Chiriboga L, Yee H, Edlin BR, et al. Hepatocyte proliferation in chronic hepatitis C: correlation with degree of liver disease and serum alpha-fetoprotein. *Liver Int*. 2004;24:198–203.
38. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C trial. *J Hepatol*. 2005;43:434–41.
39. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. *Lancet*. 1995;346:1051–5.
40. Yu ML, Huang CF, Dai CY, Huang JF, Chuang WL. Long-term effects of interferon-based therapy for chronic hepatitis C. *Oncology*. 2007;72(Suppl 1):16–23.
41. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. *Ann Intern Med*. 1998;129:94–9.
42. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. *Hepatology*. 1998;27:1394–402.
43. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. *Hepatology*. 1999;29:1124–30.
44. Okanoue T, Itoh Y, Kirishima T, Daimon Y, Toyama T, Morita A, et al. Transient biochemical response in interferon therapy decreases the development of hepatocellular carcinoma for five years and improves the long-term survival of chronic hepatitis C patients. *Hepatol Res*. 2002;23:62–77.
45. Hino K, Okita K. Interferon therapy as chemoprevention of hepatocarcinogenesis in patients with chronic hepatitis C. *J Antimicrob Chemother*. 2004;53:19–22.
46. Valla DC, Chevallier M, Marcellin P, Payen JL, Trepo C, Fonck M, et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. *Hepatology*. 1999;29:1870–5.
47. Camma C, Di Bona D, Craxi A. The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach. *Curr Pharm Des*. 2004;10:2123–30.
48. Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. *Gastroenterology*. 1999;117:1164–72.
49. Stein DF, Myaing M. Normalization of markedly elevated alpha-fetoprotein in a virologic nonresponder with HCV-related cirrhosis. *Dig Dis Sci*. 2002;47:2686–90.
50. Murashima S, Tanaka M, Haramaki M, Yutani S, Nakashima Y, Harada K, et al. A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP. *Dig Dis Sci*. 2006;51:808–12.
51. Yano H, Iemura A, Haramaki M, Ogasawara S, Takayama A, Akiba J, et al. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. *Hepatology*. 1999;29:1708–17.
52. Tarao K, Rino Y, Ohkawa S, Shimizu A, Tamai S, Miyakawa K, et al. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. *Cancer*. 1999;86:589–95.
53. Tarao K, Rino Y, Ohkawa S, Tamai S, Miyakawa K, Takakura H, et al. Close association between high serum alanine aminotransferase levels and multicentric hepatocarcinogenesis in patients with hepatitis C virus-associated cirrhosis. *Cancer*. 2002;94:1787–95.
54. Moriyama M, Matsumura H, Aoki H, Shimizu T, Nakai K, Saito T, et al. Long-term outcome, with monitoring of platelet counts, in patients with chronic hepatitis C and liver cirrhosis after interferon therapy. *Intervirology*. 2003;46:296–307.
55. Velazquez RF, Rodriguez M, Navascues CA, Linares A, Perez R, Sotorrios NG, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. *Hepatology*. 2003;37:520–7.

Original Article

ITPA gene variant protects against anemia induced by pegylated interferon- α and ribavirin therapy for Japanese patients with chronic hepatitis C

Naoya Sakamoto,^{1,2*} Yasuhito Tanaka,^{3*} Mina Nakagawa,^{1,2} Hiroshi Yatsushashi,⁴ Shuhei Nishiguchi,⁵ Nobuyuki Enomoto,⁶ Seishin Azuma,¹ Yuki Nishimura-Sakurai,¹ Sei Kakinuma,^{1,2} Nao Nishida,⁷ Katsushi Tokunaga,⁷ Masao Honda,⁸ Kiyoaki Ito,⁹ Masashi Mizokami⁹ and Mamoru Watanabe¹

¹Department of Gastroenterology and Hepatology, ²Department for Hepatitis Control, Tokyo Medical and Dental University, Tokyo, ³Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, ⁴Clinical Research Center, National Nagasaki Medical Center, Nagasaki, ⁵Department of Internal Medicine, Hyogo College of Medicine, ⁶First Department of Internal Medicine, University of Yamanashi, Yamanashi, ⁷Department of Human Genetics, Graduate School of Medicine, The University of Tokyo, Tokyo, ⁸Department of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, ⁹Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan

Aim: Host genetic variants leading to inosine triphosphatase (ITPA) deficiency, a condition not thought to be clinically important, protect against hemolytic anemia in chronic hepatitis C patients receiving ribavirin. In this study, we evaluated the clinical significance of ITPA variants in Japanese hepatitis C patients who were treated with pegylated interferon plus ribavirin.

Methods: In this multicenter retrospective cross-sectional study, 474 hepatitis C patients were enrolled who were treated with pegylated interferon plus ribavirin in four geographically different hospitals in Japan. Patients were grouped according to hemoglobin decline of more than 3 g/dL at week 4. Two single nucleotide polymorphisms (SNP) within or adjacent to the ITPA gene (rs6051702, rs1127354) were genotyped.

Results: A functional SNP, rs1127354, within the ITPA exon was strongly associated with protection against anemia with only one (0.8%) in 129 patients with the ITPA minor variant A

developing severe anemia ($P = 5.9 \times 10^{-20}$). For rs6051702, which had significant association in European-Americans, significant but weak association with severe hemoglobin reduction was found in Japanese ($P = 0.009$). In patients excluding genotype 1b and high viral load, those with the ITPA minor variant A achieved significantly higher sustained viral response rate than those with the major variant (CC) (96% vs 70%, respectively, $P = 0.0066$).

Conclusion: ITPA SNP, rs1127354, is confirmed to be a useful predictor of ribavirin-induced anemia in Japanese patients. Patients with the ITPA minor variant A (~27%) have an advantage in pegylated interferon plus ribavirin-based therapies, due to expected adherence of ribavirin doses, resulting in a higher viral clearance rate.

Key words: *c20orf194*, hemolytic anemia, hepatitis C virus, ITPA (inosine triphosphatase), pegylated interferon plus ribavirin therapy

INTRODUCTION

APPROXIMATELY 3% OF the worldwide population is infected with the hepatitis C virus (HCV), which

represents 170 million people, with 3–4 million individuals newly infected each year. Chronic hepatitis C (CHC) has a variable course; although 20–25% of CHC patients maintain persistently normal serum aminotransferases and experience relatively slow histological progression, other patients present a more active biochemical course.^{1–3} Overall, 30% of the CHC patients progress to cirrhosis in their lifetime,³ and 3–8% of cirrhosis patients develop hepatocellular carcinoma (HCC) every year.^{4–6} Among various factors, older age and hepatic steatosis are significant factors accelerating the rate of progression in CHC.^{3,7–9}

Correspondence: Professor Masashi Mizokami, Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, 1-7-1 Konodai, Ichikawa 272-8516, Japan. Email: mmizokami@hospk.ncgm.go.jp

*These authors contributed equally to this study.

Received 28 June 2010; revision 26 August 2010; accepted 20 September 2010.

Antiviral treatment has been shown to improve liver histology and decrease incidence of HCC in CHC.^{6,10} Current therapy for CHC consists of treatment with pegylated interferon (PEG IFN), which acts both as an antiviral and as an immunoregulatory cytokine, and ribavirin (RBV), an antiviral prodrug that interferes with RNA metabolism.^{11,12} However, less than 50% of patients infected with HCV genotype 1 treated in this way achieve a sustained viral response (SVR) or a cure of the infection.^{11,13} Older patients have showed a significantly lower SVR rate due to poor adherence resulting from adverse events and laboratory abnormalities.^{14–16} In particular, hematological abnormalities and RBV-induced hemolytic anemia often necessitate dose reduction and premature withdrawal from therapy in 10–14% of patients.^{11,17–20} New drugs and therapeutic approaches for CHC are actively developed and several candidates are in the early trial phase.^{21,22} Given these backgrounds, effective pre-treatment screening for predictor biomarkers with the aim to evaluate possible risks over benefits from currently available treatment would allow avoiding these side-effects in patients who will not be helped by the treatment, as well as to reduce the substantial cost of the treatment.

The completion of the Human Genome Project has led to the advent of a new era of scientific research, including a revolutionary approach: the genome-wide association study (GWAS). Several recent studies have demonstrated remarkable associations between single nucleotide polymorphisms (SNP) near or within the region of the *IL28B* gene, which codes for IFN- λ 3.^{23–28} Another recent study indicated that genetic variants leading to inosine triphosphatase (*ITPA*) deficiency, a condition not thought to be clinically important, protect against hemolytic anemia in CHC patients receiving RBV.²⁹ The results obtained in one GWAS study need to be evaluated and confirmed in the context of different geographical and racial populations, and independent cohorts. Here, we describe clinical evaluation of two SNP within or adjacent to the *ITPA* gene (6051702 and rs1127354), that was recently highlighted by the GWAS of HCV treatment-induced anemia.²⁹

METHODS

Patients

IN THIS RETROSPECTIVE cross-sectional case-control study, 474 patients with chronic HCV infection treated at Tokyo Medical and Dental University Hospi-

tal, Nagoya City University Hospital, Yamanashi University Hospital, Nagasaki Medical Center and Hyogo University of Health Science Hospital in Japan were enrolled from April 2007 to April 2009. Each patient was treated with PEG IFN- α -2b (1.5 μ g/kg s.c. once a week) or PEG IFN- α -2a (180 μ g/kg once a week) plus RBV (600–1000 mg daily depending on bodyweight). The treatment duration was set at a standard 48 weeks for genotype 1b high viral load (≥ 5 log copies/mL) patients and 24 weeks for genotype 1 low viral load (≤ 5 log copies/mL) and genotypes 2 and 3 patients. On-treatment dose reduction and discontinuation of PEG IFN or RBV were decided based on the recommendations of package inserts or clinical situations in individual patients to avoid possible side-effects. The rates of PEG IFN and RBV administration achieved were calculated as percentages of actual total dose administered of a standard total dose of 24 weeks, according to bodyweight before therapy. Hepatitis B surface antigen (HBsAg) positive and/or anti-HIV positive individuals were excluded from this study. Hemoglobin (Hb) values were measured at baseline and every week until 8 weeks. We considered Hb decline at week 4 to be a clinically important time point, as previously reported.²⁹ The threshold of Hb reduction of more than 3 g/dL was chosen as a clinically significant Hb decline according to the previous reports.^{29–31}

Informed consent was obtained from each patient who participated in the study. The study protocol conformed to the relevant ethical guidelines as reflected in a priori approval by the ethics committees of all the participating universities and hospitals.

Patient evaluation

The following factors were analyzed to determine whether they were related to the efficacy of combination therapy: age, sex, previous IFN therapy, grade of inflammation and stage of fibrosis on liver biopsy, pre-treatment biochemical parameters, such as white blood cells, neutrophils, Hb, platelet count, alanine transaminase (ALT) level, serum HCV RNA level (log IU/mL). Liver biopsy specimens were evaluated blindly, to determine the grade of inflammation and stage of fibrosis, by an independent interpreter who was not aware of the clinical data. Activity of inflammation was graded on a scale of 0–3: A0, showing no activity; A1, showing mild activity; A2, showing moderate activity; and A3, showing severe activity. Fibrosis was staged on a scale of 0–4: F0, showing no fibrosis; F1, showing moderate fibrosis; F2, showing moderate fibrosis with

few septa; F3, showing severe fibrosis with numerous septa without cirrhosis; and F4, showing cirrhosis.

SNP genotyping

Human genomic DNA was extracted from whole blood of each patient. Genetic polymorphisms, rs1127354 in *ITPA*, rs6051702 in *C20orf194*, and rs8099917 around the *IL28B* gene were determined by real-time detection polymerase chain reaction with a TaqMan probe or DigiTag2 assay typing one tag SNP located within each locus.²³ Another functional SNP, rs727010 within the *ITPA* gene, was excluded due to no variants in the Asian genetic population as reported in the International HapMap Project database. Our preliminary genotyping of a 100-patient population did not find variants in that SNP.

Outcomes

The primary end-point was Hb decline and dose reduction of PEG IFN or RBV in week 4, the secondary end-point was SVR. An SVR was defined as serum HCV RNA undetectable at 24 weeks after the end of treatment. A transient viral response (TVR) meant that HCV RNA became undetectable during treatment but reappeared at the end of follow up. A null response (NR) was defined as persistently positive HCV RNA throughout the treatment. Adverse events and drug adherence were recorded.

Statistical analyses

The association between individual *ITPA* SNP and the incidence of significant Hb decline was tested by a basic allelic test and calculated using the χ^2 -test. Multivariate logistic regression analysis with stepwise forward selection was performed with *P*-values of less than 0.05 as the criteria for model inclusion. These statistical analyses were conducted by using SPSS software package ver. 18J (Chicago, IL, USA) or Microsoft Excel Mac 2008 (Redmond, WA, USA). Discrete variables were evaluated by Fisher's exact probability test. The *P*-values were calculated by two-tailed Student's *t*-tests for continuous data and χ^2 -test for categorical data, and those of less than 0.05 were considered statistically significant.

RESULTS

THE CLINICAL CHARACTERISTICS of the 474 patients are summarized in Table 1. First, we compared baseline clinical and host genetic characteristics of patient groups according to the SNP within the *ITPA* gene, rs1127354, between major homozygote (CC) and

Table 1 Baseline characteristics of participating patients

Total number	474
Age (years)	57.2 ± 10.0
Sex (male/female)	264/210
Bodyweight (kg)	61.1 ± 10.8
HCV genotypes	
1b/2a/2b/3a	416/31/26/1
1b, high viral load/others	387/87
NS5A-ISDR mutations (genotype 1b, <i>n</i> = 334, 0–1/≥2)	285/49
Core mutations (genotype 1b, <i>n</i> = 379)	
C70 (wild/mutant)	240/139
C91 (wild/mutant)	234/145
Histology at biopsy (<i>n</i> = 278)	
Grade of inflammation (A0/1/2/3)	4/97/154/23
Stage of fibrosis (F0/1/2/3/4)	8/102/74/74/20
White blood cells (/μL)†	5707 ± 1495
Neutrophils (/μL)†	2568 ± 1013
Hemoglobin (g/dL)†	14.2 ± 1.4
Platelet count (×10 ³ /μL)†	158 ± 58
ALT (IU/L)†	89 ± 66
Serum HCV RNA (log [IU/mL])‡	6.0 ± 0.9
PEG IFN (PEG IFN-α-2a/PEG IFN-α-2b)	40/434
Hb decline at week 4 (g/dl)	2.4 ± 1.4
Severe anemia, Hb <10 g/dL at week 4	56/474 (11.8%)

†Data are expressed as mean ± standard deviation.

‡Data are shown as median (range) values.

High viral load: HCV RNA ≥ 5 log IU/mL.

ALT, alanine transaminase; Hb, hemoglobin; HCV, hepatitis C virus; IFN, interferon; ISDR, interferon sensitivity determining region; PEG, pegylated.

a group of heterozygote (CA) and minor homozygote (AA) (Table 2). There were no significant differences in age, sex, blood cell counts, ALT levels, serum viral loads, frequencies of core 70/91 mutations^{32,33} and the numbers of NS5A interferon sensitivity determining region (ISDR) mutations^{34,35} between the two groups. The SNP in the *ITPA* gene did not show significant linkage between the SNP around the *IL28B* gene, rs8099917, which is strongly associated with IFN treatment responses.^{23,25} In contrast, the SNP in the *ITPA* gene showed significant linkage with the SNP in *C20orf194*, rs6051702 (*P* = 7.1 × 10⁻¹⁴).²⁹

Next, we analyzed two SNP, rs6051702 in *C20orf194* and rs1127354 in *ITPA* loci, respectively, for their association with significant Hb decline at 4 weeks of PEG IFN plus RBV treatment using a basic allelic model that compares frequencies of alleles in cases versus controls. The SNP, rs6051702, which showed the strongest association in the European-American population,²⁹ was

Table 2 Clinical and host genetic characteristics of patients according to *IPTA* gene variants

	<i>IPTA</i> SNP, rs1127354		P-value
	CC (n = 345)	CA + AA (n = 129)	
Age (years)†	57.2 ± 10.0	57.1 ± 10.1	0.87
Sex (male/female)	192/153	72/57	0.97
White blood cells (/μL)‡	5312 ± 1537	4995 ± 1388	0.92
Neutrophils (/μL)‡	1696 ± 1415	1803 ± 1516	0.49
Hemoglobin (g/dL)‡	14.2 ± 1.4	14.1 ± 1.4	0.52
Platelet count (×10 ⁻³ /μL)‡	157 ± 54	159 ± 70	0.81
ALT (IU/mL)‡	91 ± 70	83 ± 55	0.46
Serum HCV RNA (log copies /mL)†	6.1 ± 0.7	5.8 ± 1.1	0.093
NS5A-ISDR mutations (genotype 1b, n = 334, 0–1/≥2)	213/31	72/18	0.095
Core mutations (genotype 1b, n = 389)			
aa. 70 (wild/mutant)	179/96	61/43	0.25
aa. 91 (wild/mutant)	172/103	62/42	0.60
<i>IL28B</i> , rs8099917 (TT/TG/GG)	233/94/3	96/29/1	0.23
<i>C20orf194</i> , rs6051702 (AA/AC/CC)	254/85/6	47/72/10	7.1 × 10 ^{-14*}

*P-values were calculated by student's t-test or by χ^2 analysis.

†Data are show as median (range) values.

‡Data are expressed as mean ± standard deviation.

IL28B SNP, major allele-T and minor allele-G.

C20orf194 SNP, major allele-A and minor allele-C.

ALT, alanine transaminase; HCV, hepatitis C virus; SNP, single nucleotide polymorphisms.




Figure 1 *IPTA* variant, rs1127354, known to be responsible for inosine triphosphatase deficiency and its age-related differences. *IPTA*, inosine triphosphatase. The numbers in parentheses denote numbers of patients.

associated with the Hb decline significantly but with smaller effect size (odds ratio [OR] = 1.40, $P = 9.0 \times 10^{-3}$, Table 3). Notably, another SNP in the *IPTA* gene, rs1127354, showed overwhelming association with the Hb decline (OR = 62.8, $P = 5.9 \times 10^{-20}$). The prevalence of *IPTA* variants is shown in Figure 1. Percentages of *IPTA*, rs1127354, major homozygote (CC), heterozygote (CA) and minor homozygote (AA) were 72.8%, 25.9% and 1.3%, respectively. There was no difference in the frequency of the *IPTA* variants throughout ages and sexes (Fig. 1).

To assess the clinical relevance of these SNP, we analyzed the proportion of patients suffering clinically significant anemia, which we defined as a decline in Hb levels of more than 3 g/dL or Hb levels of less than 10 g/dL, which is the threshold at which RBV dose reduction is recommended. As depicted in Figure 2, in *IPTA*-CC patients, Hb loss of more than 3 g/dL devel-

Table 3 Association of *C20orf194* and *IPTA* gene variants with treatment-induced Hb decline

Gene	SNP	Allele (major/minor)	MAF (%)	OR	P-value*
<i>C20orf194</i>	rs6051702	A/C	19.9	1.40	9.0×10^{-3}
<i>IPTA</i>	rs1127354	C/A	14.2	62.8	5.9×10^{-20}

*The SNP-phenotype associations were analyzed using a basic allelic test.

P-values were calculated by χ^2 analysis.

Hb, hemoglobin; MAF, minor allele frequency; OR, odds ratio; SNP, single nucleotide polymorphisms.




Figure 2 Effects of *c20orf194* and *ITPA* single nucleotide polymorphisms (SNP) on clinically significant anemia induced by pegylated interferon plus ribavirin treatment. Percentages of patients with hemoglobin (Hb) decline of >3 g/dL or Hb levels of >10 g/dL at week 4 of treatment are shown for each SNP in two genes, *c20orf194* (rs6051702) and *ITPA* (rs1127354).




Figure 3 Time-dependent hemoglobin (Hb) decline in *ITPA* major and minor variants. Error bars indicate mean + standard error. Asterisks 1 and 2 indicate statistical significance of $P = 6.6 \times 10^{-13}$ and $P = 3.0 \times 10^{-29}$, respectively.

oped in 48.7% at week 4, and 15.9% of patients achieved Hb levels of less than 10 g/dL. In contrast, only one patient (0.8%) with *ITPA*-CA/AA developed anemia. These differences in the incidence of the treatment-induced Hb decline were consistent throughout ages. The time-dependent Hb decline in patients with *ITPA*-CC and *ITPA*-CA/AA is shown in Figure 3. In patients with *ITPA*-CC, mean Hb drop was 2.9 ± 1.3 g/dL, which was significantly higher than that of patients with *ITPA*-CA/AA (1.1 ± 0.7 g/dL). These results demonstrate that the *ITPA* minor variant A has a protective phenotype for the treatment-induced anemia. The positive predictive value of the *ITPA*-major (CC) for the development of severe anemia was 48.7%, while the negative predictive value of *ITPA*-hetero/minor (CA/AA) was 99.2%. In accordance with the incidence of anemia, there was significant difference in the incidence of RBV dose reduction. At week 4 of treatment, RBV doses were reduced in 27.9% of *ITPA*-CC patients while in only 14.4% of *ITPA*-CA/AA patients ($P = 0.012$, Fig. 4). Similarly to RBV, PEG IFN dose reduction was apparently higher in *ITPA*-CC patients though it did not reach statistical significance.

Knowing that significantly less frequent drug reduction occurred in patients with the *ITPA*-minor variant A, we next investigated if the *ITPA* gene variants affected final treatment outcomes. The treatment outcomes were available in 339 patients with genotype 1b and high viral load




Figure 4 Percentages of patients requiring pegylated interferon (IFN) or ribavirin (RBV) dose reduction at week 4 in *ITPA* major and minor variants. Y-axis indicates percents of patients who required dose reduction. * $P = 0.012$.

Table 4 Sustained viral response rates of each group according to *ITPA* gene variants

<i>ITPA</i> SNP, rs1127354	Genotype 1b, high viral load		Others	
	CC	CA + AA	CC	CA + AA
SVR	92 (37.1%)	39 (42.9%)	41 (70%)	25 (96%)
TVR	90 (36.3%)	34 (37.3%)	15 (25%)	1 (4%)
NR	66 (26.6%)	18 (19.8%)	3 (5%)	0 (0%)
Total	248	91	59	26
<i>P</i> -value	0.33		0.0066	

High viral load; serum HCV RNA ≥ 5 logIU/mL.

"Others" include genotypes genotype 1b, serum HCV RNA < 5 logIU/ml, genotypes 2a, 2b and 3a.

P-values were calculated by χ^2 -test analyses of SVR versus TVR plus NR.

HCV, hepatitis C virus; SVR, sustained viral response; TVR, transient viral response; NR, null response.

(HCV RNA ≥ 5.0 log IU/ml) and 85 others, which included genotype 1b, low viral load and genotype 2a, 2b and 3a patients (Table 4). In patients with genotype 1b and high viral load, there was no significant difference in SVR rates between *ITPA*-CC and *ITPA*-CA/AA patients (37.1% and 42.9%, respectively). In contrast, there was a striking difference in SVR rates between *ITPA*-CC and *ITPA*-CA/AA in the other IFN-sensitive group (non-1b or low viral load); the SVR rate was 70% in *ITPA*-CC patients, while 96% of *ITPA*-CA/AA patients achieved SVR ($P = 0.0066$). These results indicate that the *ITPA* minor variant A is significantly associated with SVR in the IFN-sensitive group excluding genotype 1b and high viral load. Using those subpopulations of patients, we conducted a statistical analysis for association of several host and viral parameters with SVR. As shown in Table 5, univariate analysis identified four significant parameters including age, platelet count, stages of fibrosis and the *ITPA* SNP, rs1123354. Multivariate logistic regression

analysis identified that only age and the *ITPA* SNP were significantly associated with SVR.

DISCUSSION

RECENT GWAS ON HCV infection have identified two important host genetic polymorphisms. One is the SNP in the *IL28B* gene, which is strongly associated with response to therapy of chronic genotype 1 HCV infection,^{23–28} and another is the SNP in the *ITPA* gene, which precisely predicts RBV treatment-associated anemia in the European-American population.²⁹ In our present study, a functional SNP in the *ITPA* locus, rs1127354, is strongly associated with protection against anemia among 474 Japanese patients ($P = 5.9 \times 10^{-20}$, Table 3). Only one of 129 patients (0.8%) who carry the rs1127354 minor allele A had severe anemia (Figs 2,3). These data are consistent with the previous study in the US population²⁹ as well as a recent Japanese study by

Table 5 Univariate and multivariate logistic regression analyses of host and viral characteristics of patients excluding genotype 1b high virus load based on therapeutic responses ($n = 85$)

Variable	<i>P</i> -value (univariate)	<i>P</i> -value (multivariate)	OR	95% CI
Age	0.017	0.047	0.916	0.840–0.999
Sex (male vs female)	0.19	–		
Baseline Hb level	0.17	–		
Baseline platelet count	0.019	0.307	1.092	0.923–1.292
Stage of fibrosis (F0–2 vs 3–4)	0.0020	0.083	4.221	0.827–21.531
PEG IFN adherence ($\geq 80\%$ vs $< 80\%$)	0.67	–		
RBV adherence ($\geq 80\%$ vs $< 80\%$)	0.30	–		
<i>ITPA</i> SNP rs1127354 (CC vs CA + AA)	0.0066	0.023	12.680	1.386–116.042
<i>IL28B</i> SNP rs8099917 (TT vs TG + GG)	0.29	–		

CI, confidence interval; Hb, hemoglobin; IFN, interferon; *ITPA*, inosine triphosphatase; OR, odds ratio; PEG, pegylated; RBV, ribavirin; SNP, single nucleotide polymorphisms.

Ochi *et al.*³¹ Our data were similar to these two reports; rs1127354 was the most significant SNP that was associated with RBV-induced anemia in Asian genetic populations. Additionally, we have demonstrated that the incidence of early dose reduction was significantly higher in *ITPA*-major (CC) patients as expected (Fig. 4) and, more importantly, that a significantly higher SVR rate was achieved in *ITPA*-hetero/minor (CA/AA) patients with HCV non-1b or low viral load strains (70% vs 96%, $P = 0.0066$, Table 4). Taken together, our results demonstrate that the *ITPA* minor variant A is not only a protective allele of PEG IFN and RBV treatment-associated anemia in the Japanese population, but also a significant predictor of SVR in certain HCV strains that show good response to IFN.

An SNP in *C20orf194*, rs6051702, which showed significant association with Hb reduction in European-Americans ($P = 1.1 \times 10^{-45}$),²⁹ was also significant in our study of a Japanese population, but with smaller effect size on Hb reduction ($P = 0.014$). The discrepancy may be due to the low levels of the linkage disequilibrium (LD) with the functional SNP in the *ITPA* gene in the Japanese/Asian population as compared with the high LD in white subjects. Indeed, it is reported that the predictive values of the *C20orf194* SNP varied between different races including African-Americans ($P = 0.19$) and Hispanics ($P = 9.5 \times 10^{-3}$).²⁹

Ochi *et al.* sequenced the Japanese patient genome including *ITPA* and *DDR1* loci, which are located adjacently on chromosome 20. They identified 83 SNP with major allele frequency of more than 0.05, of which four SNP including rs1127354 were significantly associated with RBV-induced anemia and which were in almost absolute LD with each other.³¹ Their report indicates that the *ITPA* SNP, rs1127354, which we genotyped in the present study, represent a dominant variant of *ITPA* deficiency that protects against RBV-induced anemia in Japanese/Asian genetic populations. In our study, however, 51.3% of the *ITPA*-major (CC) patients did not develop significant Hb decline (Fig. 2). This finding suggests that there are other low-frequency *ITPA* variants or SNP in other enzymes that are involved in erythrocyte purine nucleoside metabolism.

The response to PEG IFN plus RBV treatment is affected by several viral and host factors such as age, sex,^{36,37} NS5A-ISDR³⁸ and core region.^{32,33} To maintain good adherence to drugs, especially RBV, it is important to achieve good treatment responses. Increased RBV exposure during the treatment phase was associated with an increased likelihood of SVR in the US³⁹ and Japanese studies.⁴⁰ Because patients with *ITPA* minor variant A are

refractory to RBV-induced anemia, they are advantaged in maintaining good adherence to RBV and may be given even higher doses of RBV, resulting in a higher SVR rate. However, a study by Fellay *et al.* and a very recent replication study by Thompson *et al.*³⁰ did not observe any significant association between the *ITPA* minor variants and early or late anti-HCV treatment outcomes.²⁹ A possible explanation for the discrepancy is that older and histologically more advanced patients were predominant in our study. Mean age in the US study was 47.5 years while 57.2 years in our present study. The percentage of advanced fibrosis (F3 or F4) was 12.0% in the US study while 34% in our study. It is well known that the incidence of drug dose reduction or discontinuation could increase according to old age as well as advanced stages, that may compromise final treatment outcomes.^{14,15} Importantly, we have additionally demonstrated that in patients with other than genotype 1b HCV, *ITPA* minor variant A was significantly associated with better SVR rates in univariate and multivariate analyses. Because the typical PEG IFN plus RBV treatment period is shorter (24 weeks) in genotype 1 low viral load and genotype 2 patients than in genotype 1 high viral load (48 weeks), early dose reduction of RBV may be more critical to the final treatment outcome.

Ribavirin is a synthetic guanosine analog, and has actions *in vitro* against a wide range of RNA and DNA viruses.⁴¹ Possible antiviral mechanisms of ribavirin include immune modulation by switching the T-cell phenotype from type 2 to type 1,⁴² anti-proliferative effect by inhibition of cellular GTP synthesis,⁴¹ and direct inhibition of virus replication.⁴³ Although monotherapy with RBV clinically showed minimal effect on the viral load and almost no effect on the viral clearance,^{44–47} combinatory use of RBV with IFN elicits strong synergistic effects against HCV *in vitro*⁴⁸ and *in vivo*.^{49,50}

Ribavirin is directly toxic to erythrocytes and is associated with hemolysis, which is usually reversible and dose-related.^{49,50} RBV is incorporated into erythrocytes where it undergoes phosphorylation to its pharmacologically active forms through adenosine kinase. The RBV-phosphate conjugates are unable to cross the erythrocyte cell membrane and are thus accumulated intracellularly and cleared slowly from red cells with a half-life of approximately 40 days.⁵¹ Inosine triphosphatase (ITP) deficiency or low activity variants, in turn, lead to an accumulation of ITP in red blood cells and may compete with RBV triphosphate, and may protect from RBV-induced hemolysis.^{52,53}

There are several STAT-C agents (specifically targeted antiviral therapies for hepatitis C) being tested for

clinical efficacy against hepatitis C.^{21,22} Most experts believe that when new drugs are approved to treat hepatitis C they will be used in combination with PEG IFN and RBV. Moreover, recent clinical trials including NS3 protease inhibitors have shown that PEG IFN plus RBV would be necessary to achieve optimal treatment responses.^{18,19,54} Our present results may give a valuable pharmacogenetic diagnostic tool for the tailoring of RBV dosage to minimize drug-induced adverse events and for further optimization of the clinical anti-HCV chemotherapeutics.

ACKNOWLEDGMENTS

THIS STUDY WAS supported by grants from the Ministry of Education, Culture, Sports, Science and Technology Japan, the Japan Society for the Promotion of Science, Ministry of Health, Labor and Welfare Japan, Japan Health Sciences Foundation, and National Institute of Biomedical Innovation.

REFERENCES

- 1 Wiese M, Grungriff K, Guthoff W, Lafrenz M, Oesen U, Porst H. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany – a 25-year multicenter study. *J Hepatol* 2005; 43: 590–8.
- 2 Santantonio T, Sinisi E, Guastadisegni A *et al.* Natural course of acute hepatitis C: a long-term prospective study. *Dig Liver Dis* 2003; 35: 104–13.
- 3 Massard J, Ratziu V, Thabut D *et al.* Natural history and predictors of disease severity in chronic hepatitis C. *J Hepatol* 2006; 44: S19–24.
- 4 Benvegna L, Gios M, Boccatto S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. *Gut* 2004; 53: 744–9.
- 5 Sangiovanni A, Prati GM, Fasani P *et al.* The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. *Hepatology* 2006; 43: 1303–10.
- 6 Yoshida H, Tateishi R, Arakawa Y *et al.* Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. *Gut* 2004; 53: 425–30.
- 7 Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. *Hepatology* 2002; 36: S47–56.
- 8 Perumalswami P, Kleiner DE, Lutchman G *et al.* Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. *Hepatology* 2006; 43: 780–7.
- 9 Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. *J Hepatol* 2001; 34: 730–9.
- 10 George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. *Hepatology* 2009; 49: 729–38.
- 11 Fried MW, Shiffman ML, Reddy KR *et al.* Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002; 347: 975–82.
- 12 Manns MP, McHutchison JG, Gordon SC *et al.* Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001; 358: 958–65.
- 13 Hadziyannis SJ, Sette H, Jr, Morgan TR *et al.* Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med* 2004; 140: 346–55.
- 14 Hiramatsu N, Oze T, Tsuda N *et al.* Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy? *Hepatol Res* 2006; 35: 185–9.
- 15 Iwasaki Y, Ikeda H, Araki Y *et al.* Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. *Hepatology* 2006; 43: 54–63.
- 16 Sezaki H, Suzuki F, Akuta N *et al.* An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads. *Intervirology* 2009; 52: 43–8.
- 17 Bruno R, Sacchi P, Maiocchi L, Patruno S, Filice G. Hepatotoxicity and antiretroviral therapy with protease inhibitors: a review. *Dig Liver Dis* 2006; 38: 363–73.
- 18 Hezode C, Forestier N, Dusheiko G *et al.* Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. *N Engl J Med* 2009; 360: 1839–50.
- 19 McHutchison JG, Everson GT, Gordon SC *et al.* Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. *N Engl J Med* 2009; 360: 1827–38.
- 20 Suzuki F, Akuta N, Suzuki Y *et al.* Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks. *Hepatol Res* 2009; 39: 1056–63.
- 21 Sakamoto N, Watanabe M. New therapeutic approaches to hepatitis C virus. *J Gastroenterol* 2009; 44: 643–9.
- 22 Sakamoto N, Wu GY. Prospects for future therapy of hepatitis C virus infection. *Future Virol* 2009; 4: 453–62.
- 23 Tanaka Y, Nishida N, Sugiyama M *et al.* Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. *Nat Genet* 2009; 41: 1105–9.
- 24 Ge D, Fellay J, Thompson AJ *et al.* Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature* 2009; 461: 399–401.
- 25 Suppiah V, Moldovan M, Ahlenstiel G *et al.* IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. *Nat Genet* 2009; 41: 1100–4.

- 26 Thomas DL, Thio CL, Martin MP *et al.* Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. *Nature* 2009; 461: 798–801.
- 27 Tanaka Y, Nishida N, Sugiyama M, Tokunaga K, Mizokami M. lambda-Interferons and the single nucleotide polymorphisms: a milestone to tailor-made therapy for chronic hepatitis C. *Hepatol Res* 2010; 40: 449–60.
- 28 Ahlenstiel G, Booth DR, George J. IL28B in hepatitis C virus infection – translating pharmacogenomics into clinical practice. *J Gastroenterol* 2010; 45: 903–10. Epub ahead of print.
- 29 Fellay J, Thompson AJ, Ge D *et al.* ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. *Nature* 2010; 464: 405–8.
- 30 Thompson AJ, Fellay J, Patel K *et al.* Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. *Gastroenterology* 2010; 139: 1181–9. Epub ahead of print.
- 31 Ochi H, Maekawa T, Abe H *et al.* ITPA polymorphism affects ribavirin-induced anemia and outcome of therapy – a genome-wide study of Japanese HCV patients. *Gastroenterology* 2010; 139: 1190–7. Epub ahead of print.
- 32 Akuta N, Suzuki F, Sezaki H *et al.* Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. *Intervirology* 2005; 48: 372–80.
- 33 Akuta N, Suzuki F, Kawamura Y *et al.* Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. *J Hepatol* 2007; 46: 403–10.
- 34 Enomoto N, Sakuma I, Asahina Y *et al.* Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. *J Clin Invest* 1995; 96: 224–30.
- 35 Enomoto N, Sakuma I, Asahina Y *et al.* Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. *N Engl J Med* 1996; 334: 77–81.
- 36 Honda T, Katano Y, Urano F *et al.* Efficacy of ribavirin plus interferon-alpha in patients aged >or=60 years with chronic hepatitis C. *J Gastroenterol Hepatol* 2007; 22: 989–95.
- 37 Hung CH, Chen CH, Lee CM *et al.* Association of amino acid variations in the NS5A and E2-PePHD region of hepatitis C virus 1b with hepatocellular carcinoma. *J Viral Hepat* 2008; 15: 58–65.
- 38 Nakagawa M, Sakamoto N, Ueyama M *et al.* Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection. *J Gastroenterol* 2010; 45: 656–65.
- 39 McHutchison JG, Lawitz EJ, Shiffman ML *et al.* Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. *N Engl J Med* 2009; 361: 580–93.
- 40 Hiramatsu N, Oze T, Yakushijin T *et al.* Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin. *J Viral Hepat* 2009; 16: 586–94.
- 41 Patterson JL, Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. *Rev Infect Dis* 1990; 12: 1132–46.
- 42 Hultgren C, Milich DR, Weiland O, Sallberg M. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. *J Gen Virol* 1998; 79: 2381–91.
- 43 Crotty S, Maag D, Arnold JJ *et al.* The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. *Nat Med* 2000; 6: 1375–9.
- 44 Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. *Lancet* 1991; 337: 1058–61.
- 45 Di Bisceglie AM, Shindo M, Fong TL *et al.* A pilot study of ribavirin therapy for chronic hepatitis C. *Hepatology* 1992; 16: 649–54.
- 46 Dusheiko G, Main J, Thomas H *et al.* Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. *J Hepatol* 1996; 25: 591–8.
- 47 Bodenheimer HC, Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. *Hepatology* 1997; 26: 473–7.
- 48 Tanabe Y, Sakamoto N, Enomoto N *et al.* Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha. *J Infect Dis* 2004; 189: 1129–39.
- 49 Davis GL, Esteban-Mur R, Rustgi V *et al.* Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. *N Engl J Med* 1998; 339: 1493–9.
- 50 McHutchison JG, Gordon SC, Schiff ER *et al.* Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. *N Engl J Med* 1998; 339: 1485–92.
- 51 Kowdley KV. Hematologic side effects of interferon and ribavirin therapy. *J Clin Gastroenterol* 2005; 39: S3–8.
- 52 Shipkova M, Lorenz K, Oellerich M, Wieland E, von Ahnen N. Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population. *Clin Chem* 2006; 52: 240–7.
- 53 Fraser JH, Meyers H, Henderson JF, Brox LW, McCoy EE. Individual variation in inosine triphosphate accumulation in human erythrocytes. *Clin Biochem* 1975; 8: 353–64.
- 54 McHutchison JG, Manns MP, Muir AJ *et al.* Telaprevir for previously treated chronic HCV infection. *N Engl J Med* 2010; 362: 1292–303.

Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis

Masayuki Kurosaki · Naoya Sakamoto · Manabu Iwasaki · Minoru Sakamoto · Yoshiyuki Suzuki · Naoki Hiramatsu · Fuminaka Sugauchi · Hiroshi Yatsunami · Namiki Izumi

Received: 22 June 2010 / Accepted: 21 August 2010
© Springer 2010

Abstract

Background This study aimed to develop a model for the pre-treatment prediction of sustained virological response (SVR) to peg-interferon plus ribavirin therapy in chronic hepatitis C.

Methods Data from 800 genotype 1b chronic hepatitis C patients with high viral load ($>100,000$ IU/ml) treated by peg-interferon plus ribavirin at 6 hospitals in Japan were randomly assigned to a model building ($n = 506$) or an internal validation ($n = 294$). Data from 524 patients treated at 29 hospitals in Japan were used for an external validation. Factors predictive of SVR were explored using data mining analysis.

Results Age (<50 years), alpha-fetoprotein (AFP) (<8 ng/mL), platelet count ($\geq 120 \times 10^9/l$), gamma-glutamyl-transferase (GGT) (<40 IU/l), and male gender were used to build the decision tree model, which divided patients into 7 subgroups with variable rates of SVR ranging from 22 to 77%. The reproducibility of the model was confirmed by the internal and external validation ($r^2 = 0.92$ and 0.93 , respectively). When reconstructed into 3 groups, the rate of SVR was 75% for the high probability group, 44% for the intermediate probability group and 23% for the low probability group. Poor adherence to drugs lowered the rate of SVR in the low probability group, but not in the high probability group.

M. Kurosaki · N. Izumi (✉)
Division of Gastroenterology and Hepatology,
Musashino Red Cross Hospital, 1-26-1 Kyonan-cho,
Musashino, Tokyo 180-8610, Japan
e-mail: nizumi@musashino.jrc.or.jp

M. Kurosaki
e-mail: kurosaki@musashino.jrc.or.jp

N. Sakamoto
Department of Gastroenterology and Hepatology,
Tokyo Medical and Dental University, Tokyo, Japan
e-mail: nsakamoto.gast@tmd.ac.jp

M. Iwasaki
Department of Computer and Information Science,
Seikei University, Tokyo, Japan
e-mail: iwasaki@st.seikei.ac.jp

M. Sakamoto
First Department of Internal Medicine, University of Yamanashi,
Yamanashi, Japan
e-mail: msakamoto@yamanashi.ac.jp

Y. Suzuki
Department of Hepatology, Toranomon Hospital, Tokyo, Japan
e-mail: suzunari@interlink.or.jp

N. Hiramatsu
Department of Gastroenterology and Hepatology,
Osaka University Graduate School of Medicine,
Osaka, Japan
e-mail: hiramatsu@gh.med.osaka-u.ac.jp

F. Sugauchi
Department of Gastroenterology and Metabolism,
Nagoya City University Graduate School of Medical Sciences,
Nagoya, Japan
e-mail: fsugauch@med.nagoya-cu.ac.jp

H. Yatsunami
Clinical Research Center, National Nagasaki Medical Center,
Nagasaki, Japan
e-mail: yatsunami@nmc.hosp.go.jp

Conclusions A decision tree model that includes age, gender, AFP, platelet counts, and GGT is useful for predicting the probability of response to therapy with peg-interferon plus ribavirin and has the potential to support clinical decisions regarding the selection of patients for therapy.

Keywords Data mining · Decision tree · Alpha-fetoprotein · HCV · Peg-interferon

Introduction

The current standard therapy for genotype 1 chronic hepatitis C is 48 weeks of pegylated interferon (PEG-IFN) plus ribavirin (RBV) [1]. Sustained virological response (SVR), defined as undetectable HCVRNA post-treatment is regarded as a cure of chronic hepatitis C. However, the rate of SVR to this regimen is only 50% in patients with HCV genotype 1b and a high HCVRNA titer [2, 3]. Since PEG-IFN and RBV combination therapy is costly and accompanied by potential adverse effects, the ability to predict the possibility of SVR before therapy may significantly influence the selection of patients for therapy. A recent report revealed that single nucleotide polymorphisms located in the *IL28B* are strongly associated with a response to PEG-IFN plus RBV therapy [4–6]. Besides, the amino acid substitutions in the NS5A [7–9] or core region of HCV were also associated with response to therapy [10, 11]. Unfortunately, these host genetic and viral factors are not yet readily available for general application in actual clinical practice. Fibrosis of the liver is also an important predictor of response, but resources may be limited in some countries. Clinical and non-invasive parameters may be better suited for general practice, but there is no established means by which the likelihood of a response can be predicted prior to therapy.

Data mining is a method of predictive analysis that explores data, without setting the hypothesis, to discover hidden patterns and relationships in highly complex datasets and enables the development of predictive models. Decision tree analysis is a core component of data mining and predictive modeling [12], and it is utilized by decision makers in various fields of business. Recent publications on decision tree analysis indicate its usefulness for defining prognostic factors in various diseases such as prostate cancer [13], diabetes [14], melanoma [15, 16], colorectal carcinoma [17, 18], and liver failure [19]. The results of the analysis are presented as a tree structure, which is intuitive and facilitates the allocation of patients into subgroups by following the flow chart form [20]. We have recently reported the usefulness of decision tree analysis for the prediction of early virological response (undetectable

HCVRNA within 12 weeks of therapy) to PEG-IFN and RBV combination therapy in chronic hepatitis C [21].

In the present study, we used decision tree analysis to explore baseline predictors of response to PEG-IFN/RBV therapy so that a pre-treatment algorithm could be created to discriminate chronic hepatitis C patients who are likely to respond to PEG-IFN/RBV therapy from those who are not. For the purpose of use in general practice, only clinical and non-invasive parameters were included in the analysis.

Materials and methods

Patients

This was a multicenter retrospective cohort study supported by the Japanese Ministry of Health, Labor and Welfare. Data were collected from a total of 800 chronic hepatitis C patients who received therapy for 48 weeks with PEG-IFN alpha-2b and RBV at Musashino Red Cross Hospital, Toranomon Hospital, Tokyo Medical and Dental University, Osaka University, Nagoya City University Graduate School of Medical Sciences, Yamanashi University, and their related hospitals. The inclusion criteria to be enrolled in this study were as follows (1) infection by genotype 1b, (2) HCVRNA higher than 100,000 IU/ml by quantitative PCR (Cobas Amplicor HCV Monitor v 2.0, Roche Diagnostic systems, CA), which is typically used for the definition of high viral load in Japan, (3) lack of co-infection with hepatitis B virus or human immunodeficiency virus, (4) lack of other causes of liver disease such as autoimmune hepatitis and primary biliary cirrhosis and (5) completion of at least 12 weeks of therapy. Patients received PEG-IFN alpha-2b (1.5 µg/kg) subcutaneously every week and were administered a weight-adjusted dose of RBV (600 mg for <60 kg, 800 mg for 60–80 kg, and 1,000 mg for >80 kg), which is the recommended dosage in Japan. Patients who were treated for more than 49 weeks were not included in the study. For the analysis, patients were randomly assigned to either the model building ($n = 506$) or the internal validation ($n = 295$) group. Consent was obtained from each patient. The study protocol conformed to the ethical guidelines of the Declaration of Helsinki and was approved by the institutional review committee. The baseline characteristics and representative laboratory test results are listed in Table 1. The overall rate of SVR was 47% in the model building set and 49% in the validation set. There were no significant differences in the clinical backgrounds between these 2 groups.

For external validation of the model, we collaborated with another study group supported by the Japanese Ministry of Health, Labor and Welfare. This multicenter study group consisted of 29 medical centers and hospitals

Table 1 Comparison of pre-treatment factors between model building and internal validation patients

	Model (n = 506)	Validation (n = 295)
Age (years)	56 (14–75)	55 (18–74)
Male gender ^a	261/506 (52%)	160/295 (54%)
Body mass index (kg/m ²)	22.9 (14.3–34.0)	23.2 (16.1–33.8)
Albumin (g/dl)	4 (2.7–5.0)	4 (2.8–4.9)
Creatinine (mg/dl)	0.7 (0.4–1.5)	0.7 (0.4–1.1)
AST (IU/l)	60 (11–370)	62 (11–240)
ALT (IU/l)	73 (11–413)	73 (14–390)
GGT (IU/l)	56 (10–328)	55 (7–409)
Total cholesterol (mg/dl)	173 (73–297)	171 (29–273)
Triglyceride (mg/dl)	105 (33–474)	109 (32–372)
White blood cell count (/μl)	4,745 (1,800–10,900)	4,823 (1,200–9,700)
Neutrophil count (/μl)	2,563 (667–7,870)	2,484 (508–7,579)
Red blood cell count (/μl)	448 (313–577)	451 (313–574)
Hemoglobin (g/dl)	14.1 (9.4–18.3)	14.1 (10.0–18.0)
Hematocrit (%)	41.7 (13.3–53.7)	41.9 (15.5–52.7)
Platelets (10 ⁹ /l)	164 (52–380)	158 (43–312)
AFP (ng/ml)	14.7 (0.9–680)	13 (0.8–323)
HCVRNA (10 ³ IU/ml)	1,852 (100–5,100)	1,870 (100–5,100)
Fibrosis stage: F3–4	73/417 (18%)	48/247 (19%)

Data expressed as median (range) unless otherwise indicated

AST aspartate aminotransferase, ALT alanine aminotransferase, GGT gamma-glutamyltransferase, AFP alpha-fetoprotein

^a Data expressed as number/available data (percentage)

belonging to the National Hospital Organization. A dataset collected from 524 patients who were treated with PEG-IFN alpha-2b/RBV was used as an external validation dataset, i.e., completely independent from the dataset that was used for model building.

Laboratory tests

Blood samples were obtained before therapy and at least once every month during therapy, and were used for hematologic tests, blood chemistry analysis and determination of HCV RNA. Pretreatment levels of HCV RNA were quantified by Cobas Amplicor (Roche Diagnostic Systems, Pleasanton, CA). SVR was defined as undetectable HCV RNA at week 24 after completion of therapy, as determined by qualitative PCR with a lower end detection limit of 50 IU/ml (Amplicor, Roche Diagnostic Systems). Liver biopsy was available in 664 patients. Fibrosis and activity

were scored according to the METAVIR scoring system [22]. Fibrosis was staged on a scale of 0–4: F0 (no fibrosis), F1 (mild fibrosis: portal fibrosis without septa), F2 (moderate fibrosis: few septa), F3 (severe fibrosis: numerous septa without cirrhosis) and F4 (cirrhosis). Activity of necroinflammation was graded on a scale of 0–3: A0 (no activity), A1 (mild activity), A2 (moderate activity) and A3 (severe activity).

Statistical analysis

A database of pretreatment variables was created containing 6 variables from hematological tests (red blood cells, hemoglobin, hematocrit, white blood cells, neutrocytes and platelets), 8 variables from the blood chemistry test [creatinine, albumin, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyltransferase (GGT), total cholesterol, triglyceride and alpha-fetoprotein (AFP)], serum level of HCV RNA and 3 variables for patient characteristics (age, gender and body mass index). Based on this database, the recursive partitioning analysis algorithm referred to as decision tree analysis was implemented to define meaningful subgroups of patients with respect to the possibility of achieving SVR.

Decision tree analysis is a family of nonparametric regression methods. Software is used to automatically explore the data to search for optimal split variables and to build a decision tree structure [23]. For the analysis, the entire study population was evaluated to determine which variables and cutoff points yielded the most significant division into 2 prognostic subgroups that were as homogeneous as possible for the probability of SVR. Thereafter, the same analytic process was applied to all newly defined subgroups. A restriction was imposed on the tree construction such that the procedure stopped when either no additional significant variable was detected or when the sample size was below 20. For this analysis, the data mining software IBM SPSS Modeler 13 (IBM SPSS Inc., Chicago, IL) was utilized. SPSS software v.15.0 (SPSS Inc., Chicago, IL) was used for multivariate logistic regression analysis.

Results

Decision tree analysis

Decision tree analysis was carried out on the model building dataset from 506 patients using 18 variables. Figure 1 shows the results. The analysis automatically selected 5 predictive variables to produce a total of 7 subgroups of patients. Age was selected as the variable of initial split with an optimal cutoff of 50 years. The possibility of achieving SVR was 41% for patients older than 50 compared to 70% for patients